Health Authority Clamps Down on Misleading Advertising
As this legal drama unfolds, it highlights the growing concerns over ethical advertising and the responsibilities of health product manufacturers in India.
In a major blow to Patanjali Ayurveda, the Uttarakhand licensing authority has suspended the licenses for 14 products manufactured by Divya Pharmacy, a unit of Patanjali. The suspension, underscored by an ongoing legal battle in the Supreme Court, stems from accusations of misleading advertisements and inappropriate health claims associated with these products. Patanjali Ayurveda is an Indian FMCG business that produces hundreds of Ayurvedic food items and pharmacy products.
Here we dissect the top five reasons leading to this significant regulatory action.
1. Misleading Advertisements and False Health Claims
The primary trigger for the license suspension was the dissemination of advertisements by Divya Pharmacy that misleadingly promoted the health benefits of their products. These advertisements claimed that the products could treat or cure various ailments and diseases, which was not substantiated by scientific evidence. This breach not only misled consumers but also violated the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, which prohibits advertisements involving a direct or implied claim for the treatment of certain diseases and disorders.
2. Supreme Court’s Intervention on Apology Publication
The issue escalated to the Supreme Court, which criticized Patanjali for not adhering to its directive to publish a proper apology for the misleading advertisements. The Court highlighted that the apology published by Patanjali was not prominent enough, comparing its size unfavorably with the full-page advertisements that had initially made the questionable claims. This disregard for the Court’s order played a significant role in the decision to suspend the product licenses.
3. Non-compliance with Regulatory Standards
Further investigations revealed that some of the suspended products did not comply with the established regulatory standards for Ayurvedic medicines. This non-compliance included discrepancies in the formulation and labeling of the products, which are critical for consumer safety and trust. Regulatory bodies have stringent guidelines to ensure that products are safe for consumption and that their labels accurately reflect their contents and usage, which Patanjali failed to adhere to.
4. Public Outcry and Medical Community Backlash
The misleading claims by Patanjali sparked significant outcry from the medical community, led by the Indian Medical Association (IMA). The IMA accused Patanjali of undermining modern medicine and public health guidelines, particularly during sensitive times such as the COVID-19 pandemic. This backlash not only damaged Patanjali’s credibility but also pressured regulatory bodies to take stringent actions to prevent further misinformation.
5. Historical Controversies and Brand Trust Erosion
Patanjali has faced multiple controversies over the years regarding its product claims and business practices. These recurring issues have eroded consumer trust and increased scrutiny from regulators and the public. The current suspension can be seen as a cumulative effect of continued scrutiny and past missteps, leading to a lower threshold for regulatory tolerance.
List of Suspended Products:
- Divya Drishti Eye Drop
- Swasari Gold
- Swasari Vati
- Bronchom
- Swasari Pravahi
- Swasari Avaleh
- Mukta Vati Extra Power
- Lipidom
- Bp Grit
- Madhugiri
- Madhunashini Vati Extra Power
- Livamrit Advance
- Livogrit
- Eyegrit Gold
(India CSR)
